Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
Key Details
- 1Median Technologies received FDA clearance for Eyonis LCS, an AI/ML-powered computer-aided detection software as a medical device.
- 2Designed to assist in the interpretation of low-dose CT (LDCT) scans for lung cancer screening, addressing inter-reader variability.
- 3Eyonis LCS is reported as the first end-to-end FDA-cleared device specifically for lung cancer screening workflows.
- 4Performance testing showed 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value (NPV).
- 5The tool is aimed at improving screening access and diagnostic accuracy, as well as reducing unnecessary procedures.
Why It Matters
FDA clearance for Eyonis LCS marks a significant advancement in AI-assisted lung cancer screening by leveraging CT imaging. The device's strong performance metrics and focus on workflow efficiency could help radiology practices meet increasing screening demands while improving patient outcomes.
Source
Radiology Business
Related News
•Radiology Business
NYC Health + Hospitals CEO Considers AI to Replace Radiologists
NYC Health + Hospitals CEO suggests AI could partially replace radiologists, pending regulatory approval.
•AuntMinnie
AI Mammography Tool Shows No Significant Benefit in Single-Reader U.S. Study
A real-world study found no significant improvement in breast cancer detection or recall rates with an FDA-approved AI mammography tool in a single-reader setting.
•Radiology Business
Prospective Study Confirms AI Boosts Lung Nodule Detection in CT Screening
A new prospective trial finds AI assistance significantly increases detection of suspicious lung nodules in low-dose chest CT screenings.